Keyphrases
Olanzapine
84%
Pharmacokinetics
82%
Antidepressants
70%
Working Memory
58%
N-acetylaspartylglutamate
56%
Cognitive Function
56%
Placebo
56%
Pharmacodynamics
48%
Antipsychotics
38%
Population Pharmacokinetics
37%
Glutamate Carboxypeptidase II (GCPII)
37%
Adverse Effects
35%
Genetic Variation
35%
Population Pharmacokinetic Model
32%
Alzheimer's Disease
30%
Cortical Efficiency
30%
Sex Differences
28%
Cabotegravir
28%
5-hydroxytryptamine
28%
Missense mutation
28%
Occupancy
28%
Quetiapine
28%
Amygdala Reactivity
28%
Long-acting Injectable
28%
SCN2A
28%
Futures Past
28%
Gene Behavior
28%
Review Update
28%
Pharmaceutical Agents
28%
Folate Hydrolase
28%
Serotonin Transporter Availability
28%
Circuitry
28%
Molecular Imaging
28%
Cortisol Level
28%
HIV Pre-exposure Prophylaxis
28%
HIV Research Network
28%
Risperidone
28%
5-HTT
28%
Late-life Depression
28%
Cytochrome P450 (CYP450)
28%
Racial Differences
28%
Imaging Genetics
28%
Antidepressant Treatment
28%
People Living with HIV (PLHIV)
28%
Reuptake
28%
KCNH2
28%
Neuroimaging Technology
28%
Human Amygdala
28%
Nimodipine
28%
Extracellular Glutamate
28%
Neuroscience
Dementia Praecox
100%
Genetic Variation
93%
Antidepressant
88%
Cognitive Function
84%
Glutamic Acid
73%
Olanzapine
70%
Working Memory
60%
Aspartic Acid
56%
Behavior (Neuroscience)
56%
Pharmacokinetics
44%
Antipsychotic
38%
Glutamate Carboxypeptidase II
37%
Functional Magnetic Resonance Imaging
36%
Individual Differences
32%
Amygdala
32%
Human Immunodeficiency Virus
28%
Missense Mutation
28%
Dehydroepiandrosterone
28%
Neurosteroid
28%
Cytochrome P450
28%
Glutamate Carboxypeptidase
28%
Nimodipine
28%
Obsessive-Compulsive Disorder
28%
Serotonin Transporter
28%
Late Life Depression
28%
Reuptake
28%
Molecular Imaging
28%
Genetic Polymorphism
28%
Typical Antipsychotic
20%
Cognitive Disorders
19%
Placebo
19%
Metabotropic Glutamate Receptor 3
14%
Positive Syndrome
14%
Neuroscience
14%
Information Processing
14%
Cortisol
12%
Bipolar Disorder
12%
Calcium Channel Blocker
12%
Citalopram
12%
Nuclear Magnetic Resonance Spectroscopy
11%
Depression
11%
Agonist
10%
Single-Nucleotide Polymorphism
9%
Selective Serotonin Reuptake Inhibitor
8%
Neural System
8%
Gray Matter
8%
L-Type Calcium Channel
8%
Brain Activation
8%
Serotonin
8%
Dorsolateral Prefrontal Cortex
8%
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacokinetics
87%
Olanzapine
67%
Prasterone
56%
Antipsychotic
42%
Antidepressant
42%
Hydrocortisone
40%
Pharmacodynamics
33%
Disease
31%
Placebo
29%
Citalopram
28%
Cabotegravir
28%
Selective Serotonin Reuptake Inhibitor
28%
HIV
28%
Model Selection
28%
Obsessive Compulsive Disorder
28%
Minimum Inhibitory Concentration
28%
Cytochrome P450
28%
Neurosteroid
28%
Glutamate Carboxypeptidase II
28%
Glutamic Acid
21%
Typical Antipsychotic
17%
Effectiveness Study
16%
Reuptake Inhibitor
14%
Sodium Chloride
14%
Serotonin
14%
Restlessness
14%
Cognitive Defect
14%
Positive Syndrome
11%
Side Effect
11%
Pharmacokinetic Modeling
11%
Symptom
9%
Perphenazine
9%
Adverse Event
7%
NONMEM
7%
Quetiapine
7%
Pythonidae
7%
Receptor
7%
Endogenous Agonist
7%
Glutamate Carboxypeptidase II Inhibitor
7%
Drug Discovery
7%
Metabotropic Receptor 3
7%
Pharmacokinetics
7%
Intramuscular Injection
6%
Drug Concentration
5%
Clinical Trial
5%
Pharmacogenetics
5%
QT Prolongation
5%
Pharmacotherapy
5%
Combination Therapy
5%
Potassium Channel
5%